Boxer Capital Management LLC Makes New Investment in Sana Biotechnology, Inc. (NASDAQ:SANA)

Boxer Capital Management LLC purchased a new stake in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,545,000 shares of the company's stock, valued at approximately $2,518,000. Boxer Capital Management LLC owned approximately 0.69% of Sana Biotechnology as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the business. Cerity Partners LLC bought a new position in Sana Biotechnology in the fourth quarter worth approximately $25,000. Tower Research Capital LLC TRC raised its position in shares of Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock worth $25,000 after acquiring an additional 10,548 shares in the last quarter. Syon Capital LLC purchased a new stake in shares of Sana Biotechnology during the 4th quarter worth $27,000. Wilmington Savings Fund Society FSB bought a new stake in Sana Biotechnology during the third quarter valued at about $29,000. Finally, Blue Trust Inc. boosted its position in Sana Biotechnology by 51.0% during the fourth quarter. Blue Trust Inc. now owns 19,823 shares of the company's stock valued at $32,000 after purchasing an additional 6,694 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on SANA shares. TD Cowen raised shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research report on Wednesday, January 8th. Citizens Jmp upgraded shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a research note on Tuesday, March 18th. HC Wainwright reaffirmed a "buy" rating and set a $11.00 price target on shares of Sana Biotechnology in a research report on Thursday, April 24th. Finally, Jefferies Financial Group started coverage on Sana Biotechnology in a report on Friday, March 14th. They set a "buy" rating and a $7.00 price objective for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Sana Biotechnology currently has an average rating of "Moderate Buy" and a consensus target price of $10.80.

Sana Biotechnology Trading Down 8.6 %

Shares of NASDAQ SANA traded down $0.16 during midday trading on Tuesday, reaching $1.71. The company had a trading volume of 2,833,020 shares, compared to its average volume of 3,301,036. Sana Biotechnology, Inc. has a 1 year low of $1.26 and a 1 year high of $10.50. The business's 50-day simple moving average is $2.00 and its 200 day simple moving average is $2.53. The stock has a market cap of $385.57 million, a P/E ratio of -1.22 and a beta of 1.75.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its earnings results on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. Analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.